Diabetes Risk Higher With 'Nonfunctional' Adrenal Tumors
Higher baseline high-sensitivity C-reactive protein (hs-CRP) is connected with less treatment-linked development in depression in patients with type 1 diabetes, according to a study published in Diabetes Care. Daniela Zahn, PhD, from the Johannes Gutenberg University Mainz in Germany, and co-workers examined the correlation between hs-CRP and depression in patients with diabetes. Participants with diabetes and major depression getting depression treatment were randomly assigned to 12 weeks of diabetes-specific sertraline treatment or group cognitive behavioral therapy and followed for 15 months. In 219 patients, hs-CRP was evaluated at baseline and at the end of the long-term period.
Type 2 diabetes increases the risk for specific kinds of cancer, according to a consensus report from the American Diabetes Association and the American Cancer Society. Diabetes doubles the danger of developing liver, pancreatic, or endometrial cancer. Certain medications used for treating type 2 diabetes may perhaps raise the danger of some types of cancers.
The researchers found that even after adjustment for confounders there were significant interactions between baseline hs-CRP and diabetes type for short- and long term improvement in depression. Higher baseline hsCRP correlated with less advancement in type 1 diabetes, but there was no significant correlation in type 2 diabetes.
"Although hs-CRP seemed to be less applicable in type 2 diabetes, including other markers of inflammation as implied by others may be required to ascertain the role of inflammation and depression outcomes in this group." Get diabetes discussions and health tips at diabetes health forum